Actively Recruiting
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Led by Sun Yat-sen University · Updated on 2026-05-01
108
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is conducted to evaluate the safety and efficiency of Penpulimab combined with AVD in patients with newly- diagnosed advanced classic Hodgkin lymphoma.
CONDITIONS
Official Title
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at consent with ECOG score 0 or 1 and expected survival over 3 months
- Diagnosis of classic Hodgkin lymphoma confirmed by histopathology
- Advanced stage disease defined as Ann Arbor stage III-IV or stage IIB with high-risk factors (mediastinal mass ratio >0.33 or mass >10 cm)
- No prior systemic treatment for classic Hodgkin lymphoma
- Measurable disease present
- Adequate function of main organs
- Female participants of childbearing potential agree to use contraception during study and for 6 months after; negative pregnancy test within 7 days before study; not breastfeeding
- Male participants agree to use contraception during study and for 6 months after
You will not qualify if you...
- Nodular lymphocyte predominant Hodgkin lymphoma or gray area lymphoma
- Classic Hodgkin lymphoma involving the central nervous system
- Active or high-risk autoimmune diseases within past 2 years requiring systemic treatment
- Use of glucocorticoids (>10 mg/day prednisone equivalent) or immunosuppressive drugs within 14 days before first treatment
- Receipt or expected receipt of live, attenuated live, or mRNA vaccines within 4 weeks before first treatment
- History of allogeneic organ or hematopoietic stem cell transplantation
- Active pulmonary tuberculosis
- History or presence of immunodeficiency including HIV or other congenital/acquired forms
- Known or suspected interstitial pneumonia or non-infectious pneumonia
- Bleeding disorders or recent severe bleeding events within 4 weeks before first treatment
- Other malignant tumors within 3 years
- Conditions affecting oral medication intake (e.g., swallowing difficulties, chronic diarrhea, bowel obstruction)
- History of substance abuse or uncontrolled mental disorders
- Any severe or uncontrollable diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
Q
Qingqing Cai, MD. PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here